Will NexGen record additional IsoEnergy impairments exceeding C$25M in FY2026?

The C$81M impairment in Q1 2025 was triggered by a 'significant and prolonged decline' in IsoEnergy's share price. Impairment accounting under IAS 28 requires a write-down when the carrying value exceeds recoverable amount. If the Q1 2025 impairment already wrote down to market value, further impairment requires IsoEnergy shares to decline further from the already-impaired level. If uranium prices remain strong (~$90/lb), IsoEnergy as a uranium explorer should have a floor on valuation. The C$25M threshold is material but achievable if IsoEnergy's share price drops significantly. Without knowing IsoEnergy's current market cap and NexGen's post-impairment carrying value, this is genuinely uncertain.

The impairment trigger is 'significant and prolonged decline' — a subjective standard. After the Q1 2025 impairment, the carrying value should be near the market value at that time. For another C$25M+ impairment at 30% ownership, IsoEnergy would need to lose ~C$83M+ in market cap from its already-impaired level. If uranium prices hold, this is unlikely for a uranium explorer. The main risk scenario is if IsoEnergy faces specific operational problems (drilling failures, permitting issues) independent of uranium prices. Without specific IsoEnergy intelligence, base case is that uranium tailwinds provide support.

Assigning slightly higher probability because exploration-stage companies are inherently volatile. IsoEnergy's share price already experienced a 'significant and prolonged decline' once. Small-cap uranium explorers can face project-specific setbacks (unfavorable drilling results, cost overruns, dilutive financings) that compress valuations independent of uranium market conditions. The fact that NexGen continued investing C$18.3M into a declining asset suggests management may have sunk cost bias. If IsoEnergy's operational outlook deteriorates, another impairment is plausible.

Post-impairment carrying value should be near market value as of Q1 2025. Further impairment requires additional decline. With uranium at ~$90/lb, the sector environment is supportive for uranium explorers. The C$25M threshold requires a material decline in IsoEnergy shares from already-reduced levels. More likely that IsoEnergy stabilizes or recovers with the uranium cycle than that it declines further. Base case is no additional material impairment.

The original impairment was driven by IsoEnergy's share price decline. If the broader uranium sector remains strong, IsoEnergy's share price should have at least modest support. However, exploration-stage companies can face company-specific risks (drilling program results, capital needs) that are independent of sector conditions. A 23% probability reflects the low base rate of repeated impairments on the same investment within one year, with a modest uplift for the demonstrated volatility of IsoEnergy's share price.

The most likely outcome is that the Q1 2025 impairment was a one-time adjustment and IsoEnergy's carrying value is now closer to market reality. Further impairment would require IsoEnergy to decline significantly from an already-reduced base during a strong uranium market. The committee identified this as a capital allocation concern but the probability of additional C$25M+ impairment specifically is relatively low. Management may also choose to sell the stake rather than take further impairments.

Post-impairment carrying value should be near market. Strong uranium prices provide sector support. Further C$25M+ impairment requires significant additional decline from already-reduced levels. Unlikely but possible.

The 2025 impairment was driven by prolonged share price decline. If uranium prices hold, IsoEnergy should stabilize. Additional impairment exceeding C$25M is a low-probability outcome unless IsoEnergy faces company-specific distress.

Exploration companies are volatile. IsoEnergy has already shown share price fragility. But the uranium cycle is supportive and post-impairment carrying value should be near market. Moderate low probability.